1T-LSD

1T-LSD, also known as 1-(thiophene-2-carbonyl)-LSD or as SYN-L-021, is an acylated derivative of lysergic acid diethylamide (LSD), which has been sold as a designer drug.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

1T-LSD, also known as 1-(thiophene-2-carbonyl)-LSD or as SYN-L-021, is an acylated derivative of lysergic acid diethylamide (LSD), which has been sold as a designer drug. It was first identified in Japan in 2023 on blotter paper misrepresented as containing 1D-LSD, but which on analysis was determined to contain 1T-LSD instead. It was also detected in Germany around the same time.

Use and effects

A 150 μg dose of 1T-LSD is said to be equivalent to 100 μg LSD. Doses of 87 to 100 μg 1T-LSD have been encountered in blotter tabs. It has also been encountered in tablets.

As a prodrug of LSD, the drug is said to produce psychoactive effects comparable to LSD. There are no data on how delayed the onset of 1T-LSD may be compared to LSD.

Analogues

Analogues of 1T-LSD include ALD-52 (1A-LSD), 1P-LSD, 1B-LSD, 1V-LSD, 1DD-LSD, and 1T-AL-LAD, among others.

Canada

1T-LSD is not a controlled substance in Canada as of 2025.

United States

1T-LSD is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

1T-LSD - Isomer Design

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368191571 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.